Idarubicin is a derivative of anthracyclines and has the same cytotoxicities. Toxic effects of idarubicin on the heart are acute and chronic, but it is less cardiotoxic than other anthracyclines. We present a case who experienced cardiac arrest during intravenous infusion of idarubicin. A 14-month old boy, diagnosed AML-M1, had been under chemotherapy treatment for six months. He was lost to follow-up after three cycles of chemotherapy. He was admitted to the hospital and diagnosed as relapse. He had cardiac arrest during the third dose of idarubicin and resuscitation was successful, but he was lost on the third day.

Keywords: idarubisin, kardiyak toksisite, çocukluk çağı, idarubicin, cardiotoxicity, childhood